Treatments for post-vaccine blood clots show promise but no ‘slam dunk,’ Canadian doctors say

A Canadian research team has published new evidence highlighting a combination of two treatments that could help patients suffering from a rare, but potentially-deadly, post-vaccine blood clot condition.

A Canadian research team has published new evidence highlighting a combination of two treatments that could help patients suffering from rare, but potentially deadly, post-vaccine blood clots. (Maggie MacPherson/CBC)

Ever since health officials announced Canada’s first known case of rare, post-vaccination blood clots back in April, scientists have been racing to learn more about what causes the potentially deadly condition — and how to treat it.

Now, a team from McMaster University in Hamilton has published new research-backed recommendations calling on clinicians to use a combination of two treatments: anti-clotting drugs alongside high doses of an intravenous, antibody-based therapy.

The potential effectiveness was outlined in three case studies featuring some of the first Canadian patients who developed post-vaccine blood clots, which was published Wednesday in The New England Journal of Medicine.

The three patients between the ages of 63 and 72 were all given a dose of the AstraZeneca-Oxford COVID-19 vaccine, the paper states, and were later diagnosed with vaccine-induced immune thrombotic thrombocytopenia (VITT).

Two developed clotting in their legs, including one who later required amputation, and the third suffered from blocked arteries and veins inside their brain.

WATCH | Researcher explains IVIG treatment:

Ishac Nazy is one of the researchers behind a new paper focused on treatments for post-vaccine blood clots, and the scientific director of the McMaster Platelet Immunology Laboratory. Here, he explains how intravenous immunoglobulin, or IVIG, works to treat patients suffering from these rare, but potentially-deadly, clots. 0:43

“What we recognized early on is that all three patients were treated with anticoagulants [or anti-clotting medication] along with intravenous immunoglobulin, or IVIG,” said Ishac Nazy, one of the researchers behind the new report and the scientific director of the McMaster Platelet Immunology Laboratory.

IVIG is a treatment made up of antibodies that can be given intravenously, and it’s long been used to help treat autoimmune conditions.

The three patients who received the treatment all survived, the paper noted.

How does IVIG work?

So how — and why — does IVIG seem to work for patients with post-vaccine blood clots?

While there’s still more research needed into why the condition happens in the first place, the study team suspects that for certain people, getting vaccinated with a viral-vector shot like AstraZeneca leads to the development of antibodies that attack a particular blood protein, which activates platelets in the bloodstream and causes them to clump together. 

IVIG treatment seems to work by flooding the system with different antibodies, which “outcompete” the patient’s own supply to prevent the chain of events leading to blood clots, Nazy explained.

The McMaster Platelet Immunology Laboratory has over 30 years of research into immune mediated platelet disorders, and operates under the direction of Ishac Nazy, left, Dr. Donald Arnold, centre, and Dr. John Kelton, right. (Submitted by McMaster University)

The team believes the therapy slows down the blood-clotting process, giving anti-clotting drugs time to work.

“This is a multi-faceted approach to try to target the clotting event from different angles,” Nazy said.

Lab work by the team found blood samples from the three patients all showed a drop in platelet activation after the treatment.

Not a ‘perfect drug’

But outside experts on blood-clotting conditions who viewed an advance copy of the paper stressed it’s just a starting point.

While the three case studies are “encouraging,” they only provide anecdotal evidence in an area that warrants far more research, said Halifax-based hematologist Dr. Sudeep Shivakumar, the interim division head and service chief for hematology at Dalhousie University’s Faculty of Medicine.

“It’s not a slam dunk,” he added, “but it does give us ideas for future studies.”

So far, there have been at least five deaths and 28 cases of vaccine-induced immune thrombotic thrombocytopenia, or VITT, reported in Canada following the countrywide distribution of more than 2.8 million doses of the AstraZeneca-Oxford vaccine. (Jeff McIntosh/The Canadian Press)

Dr. Lana Castellucci, a thrombosis physician and researcher with the Ottawa Hospital Research Institute, agrees the findings are just a jumping-off point, but says the recommendations are in line with discussions among clinicians across Canada who are navigating how to treat VITT.

Ontario’s COVID-19 Science Advisory Table, for instance, suggested both anti-clotting drugs and IVIG in its list of VITT treatment options, which formed part of the group’s interim guidance for health-care professionals back in May.

“The potential to see this as ongoing diagnosis remains, and knowing we have treatment strategies that are effective is certainly helpful,” Castellucci said.

Nazy himself acknowledged IVIG is not a “perfect drug,” and doesn’t work for every patient — noting that one of his three wound up requiring a different treatment later on, though he too eventually improved.

There have also been concerns over access and supply levels of the plasma-based treatment in recent years.

National surveillance program set up

The McMaster lab team set up a national surveillance program for VITT earlier this year and physicians around the country began sharing their clinical data, patient samples and treatment plans and progress updates.

That helped the researchers confirm VITT cases before Canadian physicians had encountered the condition, and allowed them to gauge different treatment approaches.

Months later, there are still significant unanswered questions about the mechanism behind VITT, and why it strikes certain individuals in rare circumstances.

So far, there have been at least 28 cases reported in Canada and five deaths, following the countrywide distribution of more than 2.8 million doses of the AstraZeneca vaccine.

“Is there a particular group that’s at greater risk than others?” Castellucci questioned. “Is there an age group that’s at risk? A gender more at risk — females more than males, for example?”

Guidelines allowing Canadians the choice to switch between manufacturers for each shot, and several provinces halting the use of AstraZeneca for first doses, “takes away a lot of the uncertainty” faced by many Canadians, she added.

“We know the mRNA vaccines have not seen complications like this,” Castellucci said.


U.S. vaccines may be able to make up for India’s export controls: World Bank president

The head of the World Bank says that while a shortage of vaccine supply remains the biggest hurdle to inoculating people in the developing world, increased production in the United States may be able to meet growing demand.

“If you have excess doses this month and next month, release them as quickly as you can,” says David Malpass, the President of the World Bank. He and leaders of several global organizations are urging countries to take more actions, ahead of the G7 summit, to ensure vaccine equity. 9:03

The president of the World Bank says that while a shortage of vaccines remains the biggest obstacle to inoculating people in the developing world, increased production in the United States may be able to meet growing demand. 

“We, the World Bank, have programs in 28 countries now and very quickly [we will have] 50 countries ready to provide capacity to actually administer vaccines. But still, the delivery schedules are the biggest challenge,” David Robert Malpass told CBC News Network’s Power & Politics in an interview airing today.

Malpass said that India’s decision to restrict exports of the AstraZeneca vaccine from the Serum Institute of India after a terrifying second wave started to sweep across the country has been a significant factor in the vaccine shortage in developing nations.

“But the good news side — the production runs in the U.S. have exceeded people’s high hopes. And so, the volumes of vaccines available are going up. And there should be some way to balance that,” he told guest host David Common. 

While the World Trade Organization is considering a proposal to waive patents on vaccines, Malpass said, the World Bank instead supports licensing vaccine patents to developing countries and providing funding to support production.

“The part of the World Bank called the International Finance Corporation has funding and makes debt and equity investments in companies in the developing world to make vaccines. And we’ll be making announcements on that over the next two weeks,” he said.

You can watch full episodes of Power & Politics on CBC Gem, the CBC’s streaming service.


The difficulty of vaccinating the world against COVID-19 is enormous

Uneven distribution of coronavirus vaccines worldwide is raising concerns about potential new variants while fuelling economic problems and unrest.

As Canada reopens, about 88 per cent of the world hasn’t had a single COVID-19 shot and experts warn the glaring inequality is a threat to everyone trying to escape the pandemic. 7:26

As G7 ministers prepare to meet this week in Cornwall, U.K., there are renewed calls to increase global vaccine manufacturing, as well as rising concerns over a “two-track pandemic” favouring wealthier nations as vaccinations in poorer countries lag.

The World Health Organization (WHO) has long said that the pandemic ends when everyone is vaccinated against COVID-19, and it initially hoped to have 20 per cent of the global population inoculated by the end of 2021. That is looking less and less achievable, since 88 per cent of the world has not yet had a single dose, and delivering the vaccine to many populations in need is being hampered by politics and nationalism.

“I’d be worried about the 39 or 40 countries that have vaccinated only one per cent of their population,” said Rohinton Medhora, president of the Centre for International Governance Innovation, citing concerns over newer variants that could arise. 

“These might not be countries that are on the tips of tongues of Canadians and Americans every day. But as I’ve said before, this is where the bad things will emanate from.” 

Achal Prabhala, who studies access to medicines with AccessIBSA in Bangalore, India, notes a point towards the end of May when the pandemic’s course changed. COVID-19 deaths were initially higher in wealthier countries, perhaps because they tend to have older populations. But as vaccines became available and were scooped up by richer nations, death rates dropped below those in lower-income countries for the first time. The poorest countries with the weakest infrastructure are now seeing the most deaths and illness.

Prior to that point, the world “was experiencing the same problem,” Prabhala said.

“When poor countries are left to themselves for a disease that primarily affects them, it will mean that they will be worse off and have less resources to deal with that,” Prabhala added.

Rohinton Medhora, president of the Centre for International Governance Innovation, said he has seen an estimate that global herd immunity may not be achieved until 2023 or 2024 based on current vaccination rates. (CBC)

Medhora says international cooperation is crucial to ending the pandemic, pointing to the 20-year campaign to end smallpox — which required the U.S. and then-U.S.S.R. to work together — as an example of success.

“We will need about 10 to 12 billion doses this year if we want to inoculate every adult around the world. The optimistic forecasts for production of all the vaccines that we know kind of add up to 10 billion,” Medhora said. “But that still is [by] the end of the year.”

Additionally, some wealthier countries are monopolizing the vaccine supply. 

“It is highly unlikely that just because we produce 10 billion, everyone who needs them will get them,” Medhora said. 

“The estimate that I’ve seen is that if you want to achieve what might be global herd immunity, we’re looking at 2023 to 2024 for the world as a whole,” he added.

Manufacturing issues

COVID-19 Vaccines Global Access (COVAX) — a global initiative to distribute doses that’s backed by the WHO, along with other health groups and national governments — was meant to fill the gap for countries unable to produce vaccines or negotiate contracts themselves. It had pledged to deliver 237 million doses to 142 countries by the end of May this year, but was only able to ship 80 million. (Canada, which does not manufacture vaccines, has supported COVAX but also drawn from it, the only G7 nation to do so.)

COVAX and the WHO are now calling on countries to donate their excess doses to help make up the shortfall.

The U.S. announced it will be offering millions of doses, and pharmaceutical company Pfizer says it will donate two billion over the next year. But the gap between vaccine “have” and “have not” countries remains a problem.

WATCH | COVAX chair asks Canada and other countries to donate surplus doses:

“From COVAX’s perspective, we would like them as soon as possible,” said Gavi’s José Manuel Barroso, “and at the same time, I understand that governments want to be sure that they have enough for their own populations.” 8:21

Bangladesh, for example, with a population of 163 million, only received its first shipment of 100,000 Pfizer vaccines on May 31.

Part of the reason for the shortfall in vaccine deliveries to some nations, both directly and through COVAX, is that it is a complicated business to make and distribute them, says Prabhala.

One of the issues is that vaccines are protected by intellectual property laws, and only facilities licensed by the pharmaceutical companies that own the patents are permitted to make them.

“So somebody has to literally give you the permission to make a vaccine,” Prabhala explained, noting that manufacturers also need access to raw materials and infrastructure. 

“And none of this can happen unless the technology is shared.”

Some countries are calling for a waiver to be signed by member nations of the World Trade Organization (WTO), due to the unique circumstances of the pandemic, allowing other manufacturers to make and distribute the vaccine without licences from the pharmaceutical companies that own the patents.

U.S. President Joe Biden has supported the idea. However, a majority of WTO countries, including Canada and Germany, have not. All WTO countries must vote in favour of the waiver for it to pass.

WATCH | Joe Biden backs waiving vaccine patents:

The Biden administration has joined calls for more sharing of the technology behind COVID-19 vaccines to help speed the end of the pandemic, amid a debate over lifting intellectual property protections. 3:35

“And so the kinds of things I’m working on right now are to say, this is great that we started the conversation, but please, let’s finish it because it’s a long, long way from being done,” Prabhala said.

“I would argue that the vaccines that we now have on the market were not developed only by the pharmaceutical companies,” Medhora added. “They were heavily subsidized by taxpayers in many countries, including ours. Therefore, some of that intellectual property does belong in the public domain.”

Pharmaceutical companies argue that opening up the patents won’t speed up vaccinations, due to a lack of global manufacturing capacity and raw materials for vaccines.

India, a global leader in vaccine manufacturing, was responsible for fulfilling COVID-19 vaccine contracts for COVAX before the country was engulfed in its deadly second wave. It cancelled its export contracts to focus on manufacturing for its own population.

Countries waiting for doses from COVAX, particularly those in Africa, have fallen behind other countries that have been able to negotiate contracts directly with vaccine manufacturers. 

“One of the problems is that any country that woke up late to understand that it needs a large supply of vaccines is now at the back of the queue,” Prabhala said. 

In response, on Tuesday the Mastercard Foundation announced a donation of $ 1.3 billion in partnership with the African Union Centre for Disease Control to help bring more doses to the continent. That money will help vaccinate 50 million people, and boost local vaccine manufacturing.

Achal Prabhala, who studies access to medicines with AccessIBSA in Bangalore, India, said the complexity of making and delivering vaccines is part of the reason for the shortfall in deliveries to some nations, both for direct contracts and through COVAX. (CBC)

Global inequalities

The inequality of vaccine distribution is more than a health issue. It’s causing economic problems and fuelling unrest.

In Venezuela, where just 11 per cent of the population has received one shot, people are protesting and demanding the government secure more vaccines. Venezuela has not received any doses from COVAX yet, has refused AstraZeneca due to health concerns, and the U.S. will not allow any of the vaccines it is donating to other nations to be used there.

Dr. Julio Castro, an infectious diseases specialist in Caracas, says the country is hoping to receive 11 million mRNA doses from COVAX between July and December. 

Meanwhile, Venezuelan president Nicolas Maduro announced the arrival of vaccines from China and Russia last month, as well as the beginning of a national vaccination campaign, but a weak health care system and infrastructure could hamper the rollout. There are also concerns about the worsening humanitarian crisis in the country involving a mass exodus of people, including doctors, along with growing malnutrition and calls for aid. 

Dr. Castro says he is seeing a growing black market in vaccines, with people selling doses for hundreds of dollars online and administering them in people’s homes. “This is irregular, unethical, and this is dangerous for people.”

Dr. Julio Castro, an infectious diseases specialist in Caracas, said the country is hoping to receive 11 million mRNA doses before the end of the year. (Leo Alvarez)

Nigeria, in contrast, has relied on COVAX and the African Union for its doses. So far, less than one per cent of its population is vaccinated.

“Nigeria has some vaccines,” said Edwin Ikhuoria, Africa Executive Director at the ONE Campaign, an organization working to eradicate preventable disease. “But we are yet to distribute about 50 per cent of them, simply because the government of Nigeria decided that we don’t know when the next batch will come.”

Ikhouria says COVID-19 is having a major economic impact on Nigeria, with exports drastically reduced. Unemployment has risen to 33 per cent and urgent action is needed.

“I don’t get any help from anybody, I don’t get help from any government, I am on my own,” said Nafisat Iliyasu Adamu, 30, who lost her job at a bank in November 2020. She has since been living in a guesthouse in Abuja. 

“It’s very scary. How can a young woman like me survive without a job?” she said, noting that high unemployment has also resulted in an increase in crime and violence. She says people need to get vaccinated to bring the economy back.

Nafisat Iliyasu Adamu of Abuja, Nigeria, said high unemployment caused by COVID-19 has also brought an increase in crime and violence. (CBC)

Ikhuoria says that the best-case scenario sees the pandemic ending in 2022, if countries come together and help those struggling. If governments continue to take a nationalistic approach, “we might go on like this for the next four or five years.”

While countries like the U.S. and Canada are thinking about easing pandemic health measures, Ikhuoria says officials have to remain mindful of what is happening in other parts of the world so no one is left behind.

“As long as this virus remains in those places, it [will] continue to mutate. It will come back to your own population in the long run, and every effort you’ve made before will be wasted.” 

He also makes an economic argument for helping other countries with their rollouts.

“Once the virus is rampaging in other places of the Earth, everything that Canada needs from those places or is supposed to be selling to those places will not be there,” he said. “The sooner we deal with the pandemic everywhere, the sooner the world returns to normalcy.” 

Ikhuoria says he hopes the sentiment that began the pandemic can help end it: We are all in this together.

Watch full episodes of The National on CBC Gem, the CBC’s streaming service.


2 paramedics found guilty in death of Hamilton teen Yosif Al-Hasnawi

Two Hamilton paramedics who treated dying teenager Yosif Al-Hasnawi in 2017 are guilty of failing to provide the necessaries of life, an Ontario Superior Court judge has found.

Yosif Al-Hasnawi, 19, was shot and killed in Hamilton on Dec. 2, 2017. (Al-Mostafa Islamic Centre)

Two Hamilton paramedics who treated dying teenager Yosif Al-Hasnawi in 2017 are guilty of failing to provide the necessaries of life, an Ontario Superior Court judge has found.  

Steven Snively, 55, and Christopher Marchant, 32, had pleaded not guilty.

“To say this is a tragic case would be a gross understatement,” Justice Harrison Arrell said in delivering his decision  Tuesday.

The 19-year-old’s father Majed Al-Hasnawi, reacted to the finding by saying, “I think it’s very fair. They are guilty. I’m not concerned if they take 10 years in jail or one. I’m not about that. I’m happy.”

Yosif was in Hamilton’s lower city on the night of Dec. 2, 2017, when he was shot in the abdomen. 

The court heard Snively and Marchant believed the teen had been shot with a BB or pellet gun. In fact, Al-Hasnawi was shot with a .22-calibre handgun, and the hollow-point bullet pierced an artery and vein. 

It took paramedics 23 minutes to leave the scene at Main and Sanford that night, the court heard. The teen was shot at 8:55 p.m. ET, and pronounced dead at St. Joseph’s Hospital about an hour later.

Union leader says appeal is possible

The court has scheduled a two-day sentencing hearing for Oct. 25 and 26. The conviction carries a sentence that cannot exceed five years.

Mario Posteraro, president of OPSEU Local 256, which represents Hamilton paramedics, said legal counsel will review the decision.

The defendants were “obviously looking for a different outcome,” he said, and appealing is “always a possibility.”

“This is a sad and tragic event. There’s no verdict, no outcome that can change the events of Dec. 2 for the Al-Hasnawi family, so we do feel for them, ” Posteraro said. 

“We’re tasked to make multiple critical decisions, rapidly and simultaneously under very difficult circumstances. We stand by our paramedics and the work that they do in the City of Hamilton.” 

He has said the charges will have serious implications for the field.

“These precedent-setting criminal charges are game-changers for our paramedic profession,” he said in 2018.

Snively and Marchant are on the same release pending their sentencing, according to one of the lawyers. 

Paramedics listened to ‘rumours,’ judge said

In his decision, Arrell said paramedics are taught that a penetrating wound to a person’s abdomen is an immediate “load and go” to a lead trauma hospital, but they failed to follow training and protocols.

Instead, they “listened to rumours and innuendos” at the scene that the wound was superficial and could not be serious, “and as such deprived Yosif of his only possible chance of survival,” said the judge.

Firas Al Najim, a human rights activist, Yosif’s dad, Majed Al-Hasnawi, and Yosif’s younger brother, Ahmed Al-Hasnawi, left to right, hold a photo of Yosif outside the Hamilton courthouse. (CBC News)

Arrell said Snively’s and Marchant’s actions that night amounted to a “marked departure” from the minimum standard expected of properly trained paramedics.

He pointed to three issues:

  • Failure to properly identify that the wound was a penetrating one.
  • Their participation in dangerous lifts to move him from the sidewalk.
  • The delay in leaving the scene.

“I conclude these various failures by the accused were not simple inadvertence, thoughtlessness or simple errors in judgment, but instead were a conscious decision to ignore their training and standards,” said Arrell.

“I also conclude that as a result of these various failures of the accused, it was objectively and reasonably foreseeable that they were risking Yosif’s life and permanently endangering his health.”

Firas Al Najim, a family friend and human rights activist, said they’re happy to see “some justice served.” 

“Hopefully there’s not going to be any case in the future. The paramedics are going to know not to deal with a patient like this,” he said. 

“When he’s telling you he can’t breathe, if he’s hurt, just take him to the trauma centre.  Do your job.  You’re not there to see if he’s acting.” 

Justice Harrison Arrell reads his judgement at Hamilton court in the trial of two paramedics charged in the death of Hamilton teen Yosif Al-Hasnawi. (Pam Davies/CBC)

Defence argued mistakes were non-criminal

Arrell presided over the judge-alone trial, which started in November 2020. 

Crown attorneys Scott Patterson and Linda Shin had argued the paramedics ignored their training and departed from provincial standards. In closing arguments, they called the medical care the pair provided “grossly negligent.”

But the defence said the paramedics were following unconscious biases that night, which led them astray in treating Al-Hasnawi. 

They also said that while some of the paramedics’ actions may have been mistakes, it didn’t necessarily mean they were criminally responsible.

Both of the accused testified on their own behalf and said they thought Al-Hasnawi was experiencing a psychiatric emergency. 

Jeffrey Manishen of Hamilton represented Marchant and Michael DelGobbo of St. Catharines represented Snively. 

Other witnesses who testified included medical experts, dispatchers and first responders — firefighters and police officers — as well as bystanders, including Al-Hasnawi’s family members, who were there that night.

Arrell said that life was “snuffed out” that night, with the teen attempting to be a “Good Samaritan.”

Al-Hasnawi was outside a Main Street E. mosque on Dec. 2 with one of his brothers and others. 

The shooting happened after he intervened when he saw two people accost an older man. 

Dale King, the man who shot Al-Hasnawi, was acquitted last year of second-degree murder. That decision is being appealed.


Bangladesh locks deal with China to buy Sinopharm Covid-19 vaccines

Bangladesh has signed a deal with China to buy Sinopharm Covid-19 vaccines.

Health Minister Zahid Maleque disclosed the information during a programme at the National Institute of Cardiovascular Diseases in Dhaka today.

For all latest news, follow The Daily Star’s Google News channel.

Earlier the revelation regarding the price of the jabs created some issues, the minister said.

“This time, strict privacy will be maintained regarding this according to the contract,” he added.

Stay updated on the go with The Daily Star Android & iOS News App. Click here to download it for your device.


Type START BR and send SMS it to 22222


Type START BR and send SMS it to 2222


Type START BR and send SMS it to 2225


Covid-19: 4 die, 21 infected in 24 hours in Thakurgaon

Four people died from Covid-19 and 21 were infected in 24 hours (till 8am today) in Thakurgaon.

Civil Surgeon Dr Mahfuzar Rahman said, four persons from four upazilas died from coronavirus while 21 tested positive out of 46 samples tested in 24 hours. In the last 11 days, 13 people had died from Covid-19 in the district, reports our Thakurgaon correspondent.

For all latest news, follow The Daily Star’s Google News channel.

In May 2021, 46 out of 330 samples tested were detected with Covid-19 infection but in June (till today), the number of detections stands at 228 out of 612 samples, Mahfuzar added.    

So far, 1,915 people have been diagnosed with the virus in the district. Of them, 1,596 people have recovered. The death toll from Covid-19 reached 49 today in the district, he said.  

According to the civil surgeon, 22 people were detected with Covid-19 on June 7, 30 on June 8, 39 on June 9, 43 on June 10, and 21 on June 11.

The district and police administration set up check posts in each entry point of the district to make sure people are following health guidelines properly, said Mahfuzar.


Mexico says Covid-19 has affected a fourth of its population

About a quarter of Mexico’s 126 million people are estimated to have been infected with the coronavirus, the health ministry said on Friday, far more than the country’s confirmed infections.

The 2020 National Health and Nutrition Survey (Ensanut) showed that about 31.1 million people have had the virus, the ministry said in a statement, citing Tonatiuh Barrientos, an official at the National Institute of Public Health.

For all latest news, follow The Daily Star’s Google News channel.

The estimate was given as the country recorded 3,282 new cases and 243 more fatalities, taking its total number of confirmed infections to 2,448,820 and the death toll to 229,823.

The government has said previously the real number of cases was likely to be significantly higher.

According to Barrientos, not all of the people in the survey’s estimate necessarily showed symptoms. The survey was based on interviews with people at 13,910 households between Aug. 17 and Nov. 14 last year, and confirmed preliminary results released in December.

Separate data published in March suggested Mexico’s actual death toll was at least 60 percent above the confirmed figure.


Covid-19 deaths cross 13,000 mark in the country

Forty-three people have died from Covid-19 in 24 hours (till 8am today), according to a press release issued by the Directorate General of Health Services (DGHS).

With this, the total number of deaths has reached 13,032 and death rate stands at 1.58 percent.

For all latest news, follow The Daily Star’s Google News channel.

At least 2,454 new infections were recorded in the meantime taking the total number of people infected to 8,22,849, added the release.

The current positivity rate is 13.24 percent and the total positivity rate is 13.39 percent.

A total of 18,535 samples were tested across the country in 24 hours (till 8am today).

At least 2,286 Covid-19 patients have recovered during the period.

The total number of recoveries now stands at 7,61,916 and the recovery rate stands at 92.59 percent.

Among the 43 deceased, 30 were men and 13 were women. Of them, one was between 21-30 years old; two between 31-40 years old, four between 41-50, 11 between 51-60, and 24 were above 60 years, added the release.


Current Covid-19 positivity rate up at 13.25%

Forty people have died from Covid-19 during 24 hours (till 8am today), according to a press release issued by the Directorate General of Health Services (DGHS).

With them, the total number of deaths so far reached 12,989 and death rate stands at 1.58 percent.

For all latest news, follow The Daily Star’s Google News channel.

At least 2,576 new infections were recorded in the meantime taking the total number of people infected to 8,20,395, added the release.

The current positivity rate is 13.25 percent.

A total of 19,447 samples were tested across the country in 24 hours (till 8am today).

At least 2,061 Covid-19 patients have recovered during the period.

The total number of recoveries now stands at 7,59,630 and the recovery rate at 92.59 percent.

Among the 40 deceased, 31 were men and nine women while one was between 0-10 years old; one was within 21-30; one between 31-40 years old, seven between 41-50, eight within 51-60, and 22 were above 60 years old, added the release.


18 dengue patients undergoing treatment at Dhaka hospitals: DGHS

Eighteen dengue patients are receiving treatment at different hospitals in Dhaka until this morning as number of the mosquito-borne disease started to rise across the country.

Five new cases of dengue have been reported in the 24 hours, the Directorate General of Health Services (DGHS) said in a media release.

For all latest news, follow The Daily Star’s Google News channel.

A total of 129 patients have been admitted to different hospitals with dengue since January and 111 of them recovered.

The health authorities reported 1,193 dengue cases and three confirmed dengue-related deaths in 2020.